Torabi Mohammadreza, Sardari Soroush, Rodríguez-Martínez Alejandro, Arabi Nooshin, Pérez-Sánchez Horacio, Ghasemi Fahimeh
Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Medical Biotechnology Department, Drug Design and Bioinformatics Unit, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Mol Divers. 2025 May 26. doi: 10.1007/s11030-025-11214-6.
Tumor cell survival depends on the presence of oxygen and nutrients provided by existing blood vessels, particularly when cancer is in its early stage. Along with tumor growth in the vicinity of blood vessels, malignant cells require more nutrients; hence, capillary sprouting occurs from parental vessels, a process known as angiogenesis. Although multiple cellular pathways have been identified, controlling them with one single biomolecule as a multi-target inhibitor could be an attractive strategy for reducing medication side effects. Three critical pathways in angiogenesis have been identified, which are activated by the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR). This study aimed to develop a methodology to discover multi-target inhibitors among over 2000 FDA-approved drugs. Hence, a novel ensemble approach was employed, comprising classification and regression models. First, three different deep autoencoder classifications were generated for each target individually. The top 100 trained models were selected for the high-throughput virtual screening step. After that, all identified molecules with a probability of more than 0.9 in more than 70% of the models were removed to ensure accurate consideration in the regression step. Since the ultimate aim of virtual screening is to discover molecules with the highest success rate in the pharmaceutical industry, various aspects of the molecules in different assays were considered by integrating ten different regression models. In conclusion, this paper contributes to pharmaceutical sciences by introducing eleven diverse scaffolds and eight approved drugs that can potentially be used as inhibitors of angiogenesis receptors, including VEGFR, FGFR, and EGFR. Considering three target receptors simultaneously is another central concept and contribution used. This concept could increase the chance of success, while reducing the possibility of resistance to these agents.
肿瘤细胞的存活依赖于现有血管提供的氧气和营养物质,尤其是在癌症早期阶段。随着肿瘤在血管附近生长,恶性细胞需要更多营养;因此,亲代血管会发生毛细血管芽生,这一过程称为血管生成。尽管已经确定了多种细胞途径,但用单一生物分子作为多靶点抑制剂来控制它们可能是一种减少药物副作用的有吸引力的策略。已经确定了血管生成中的三条关键途径,它们由血管内皮生长因子受体(VEGFR)、成纤维细胞生长因子受体(FGFR)和表皮生长因子受体(EGFR)激活。本研究旨在开发一种方法,在2000多种FDA批准的药物中发现多靶点抑制剂。因此,采用了一种新颖的集成方法,包括分类和回归模型。首先,针对每个靶点分别生成三种不同的深度自动编码器分类。选择前100个训练模型用于高通量虚拟筛选步骤。之后,去除所有在超过70%的模型中概率大于0.9的已识别分子,以确保在回归步骤中进行准确考虑。由于虚拟筛选的最终目标是发现制药行业中成功率最高的分子,通过整合十种不同的回归模型,考虑了不同测定中分子的各个方面。总之,本文通过引入十一种不同的支架和八种已批准的药物为药物科学做出了贡献,这些药物有可能用作血管生成受体(包括VEGFR、FGFR和EGFR)的抑制剂。同时考虑三种靶受体是另一个核心概念和贡献。这一概念可以增加成功的机会,同时降低对这些药物产生耐药性的可能性。